ASP Isotopes (NASDAQ:ASPI) Director Michael Gorley Sells 64,000 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) Director Michael Gorley sold 64,000 shares of ASP Isotopes stock in a transaction dated Tuesday, September 30th. The stock was sold at an average price of $9.75, for a total transaction of $624,000.00. Following the sale, the director directly owned 81,360 shares of the company’s stock, valued at $793,260. The trade was a 44.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

ASP Isotopes Stock Up 3.9%

Shares of ASPI opened at $9.34 on Friday. The firm has a market cap of $858.44 million, a P/E ratio of -15.31 and a beta of 3.29. The company has a debt-to-equity ratio of 3.53, a quick ratio of 14.56 and a current ratio of 14.72. ASP Isotopes Inc. has a 52 week low of $2.78 and a 52 week high of $11.86. The firm’s 50-day simple moving average is $9.53 and its 200 day simple moving average is $7.75.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.92). ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%.The firm had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.60 million. On average, analysts forecast that ASP Isotopes Inc. will post -0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ASPI shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a report on Wednesday, September 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $11.00.

Institutional Trading of ASP Isotopes

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. raised its holdings in ASP Isotopes by 41.2% during the second quarter. Ameritas Investment Partners Inc. now owns 5,483 shares of the company’s stock worth $40,000 after buying an additional 1,600 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of ASP Isotopes by 84.9% during the second quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares during the last quarter. SBI Securities Co. Ltd. increased its position in shares of ASP Isotopes by 84.8% during the first quarter. SBI Securities Co. Ltd. now owns 9,370 shares of the company’s stock worth $44,000 after acquiring an additional 4,299 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of ASP Isotopes by 96.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,890 shares of the company’s stock worth $80,000 after acquiring an additional 5,353 shares during the last quarter. Finally, Millennium Management LLC bought a new position in ASP Isotopes in the 4th quarter valued at about $55,000. Institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.